Fu, Xue Jun
Nozu, Kandai
Kaito, Hiroshi
Ninchoji, Takeshi
Morisada, Naoya
Nakanishi, Koichi
Yoshikawa, Norishige
Ohtsubo, Hiromi
Matsunoshita, Natsuki
Kamiyoshi, Naohiro
Matsumura, Chieko
Takagi, Nobuaki
Maekawa, Kohei
Taniguchi-Ikeda, Mariko
Iijima, Kazumoto
Article History
Received: 8 January 2015
Revised: 24 April 2015
Accepted: 29 April 2015
First Online: 27 May 2015
Competing interests
: KI received grants from Novartis Pharma K.K., Japan Blood Product Organization, Kyowa Hakko Kirion Co., Ltd, JCR Pharmaceuticals Co., Ltd, AbbVie Inc., Genzyme Japan K.K., Teijin Pharma Ltd, Daiichi Sankyo Co., Ltd, and Miyarisan Pharmaceutical Co., Ltd, and lecture fees from Kyowa Hakko Kirin Co., Ltd, Astellas Pharma Inc., Pfizer Japan Inc., Asahi Kasei Pharma Corp., Kowa Pharmaceutical Co., Ltd, Merck Sharp & Dohme Corp., Alexion, Meiji Seika Pharma Co., Ltd, and Novartis Pharma K.K.. KI is also an advisor for Zenyaku Kogyo Co., Ltd.